Spero Therapeutics, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Spero Therapeutics, Inc. (SPRO) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$1.14 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-14.
Discontinued › Income Statement
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2019-03-14
- Spero Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2017-12-31 was -$6.00K.
- Spero Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2017-09-30 was -$8.00K.
- Spero Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2017-06-30 was -$594.00K.
- Spero Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2017-03-31 was -$535.00K.
- Spero Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2017 was -$1.14M.
- Spero Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2016 was -$7.15M.
- Spero Therapeutics, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2015 was -$3.00M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$14.00K derived: sum of 2 quarters · filed 2019-03-14 | -$608.00K derived: sum of 3 quarters · filed 2019-03-14 | -$1.14M 10-K · filed 2019-03-14 |
| 2017-09-30 | -$8.00K 10-Q · filed 2018-11-08 | -$602.00K derived: sum of 2 quarters · filed 2018-11-08 | -$1.14M 10-Q · filed 2018-11-08 | -$2.12M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | -$594.00K 10-Q · filed 2018-08-09 | -$1.13M 10-Q · filed 2018-08-09 | -$2.12M derived: sum of 3 quarters · filed 2019-03-14 | -$3.72M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-03-31 | -$535.00K 10-Q · filed 2018-05-10 | -$1.52M derived: sum of 2 quarters · filed 2019-03-14 | -$3.12M derived: sum of 3 quarters · filed 2019-03-14 | |
| 2016-12-31 | -$986.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$2.59M derived: sum of 2 quarters · filed 2019-03-14 | -$7.15M 10-K · filed 2019-03-14 | |
| 2016-09-30 | -$1.60M 10-Q · filed 2017-12-14 | -$6.16M 10-Q · filed 2017-12-14 | ||
| 2015-12-31 | -$3.00M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |